JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Inicio・Lista de Acciones・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Cerrado

SectorSalud

201.37 -0.95

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

198.52

Máximo

203.54

Métricas clave
By Trading Economics
Ingresos	56M -39M
Ventas	57M 158M
Margen de beneficio	-24.585
Empleados	1,017
EBITDA	51M 2.3M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+26.47% upside

Dividendos
By Dow Jones
Próximas Ganancias	13 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	1.2B 12B
Apertura anterior	202.32
Cierre anterior	201.37

Noticias sobre sentimiento de mercado

By Acuity

50%

160 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

157.66 / 167.29 Soporte y Resistencia

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

31 oct 2025, 17:40 UTC

Adquisiciones, fusiones, absorciones

Orange to Buy Lorca's 50% Stake in MasOrange for $4.9 Billion

31 oct 2025, 23:09 UTC

Ganancias

Review & Preview: October Surprise -- Barrons.com

31 oct 2025, 22:44 UTC

Adquisiciones, fusiones, absorciones

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31 oct 2025, 21:25 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

31 oct 2025, 21:20 UTC

Adquisiciones, fusiones, absorciones

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

31 oct 2025, 21:12 UTC

Adquisiciones, fusiones, absorciones

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

31 oct 2025, 21:12 UTC

Adquisiciones, fusiones, absorciones

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31 oct 2025, 21:12 UTC

Adquisiciones, fusiones, absorciones

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

31 oct 2025, 20:51 UTC

Adquisiciones, fusiones, absorciones

Another Rare-Earth Stock Jumps on Government Deal -- Barrons.com

31 oct 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

31 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

31 oct 2025, 20:50 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

31 oct 2025, 20:46 UTC

Adquisiciones, fusiones, absorciones

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

31 oct 2025, 20:22 UTC

Ganancias

Amazon Stock Hits New Record. What Was So Good in Its Earnings Report. -- Barrons.com

31 oct 2025, 20:02 UTC

Ganancias

Meta Faces a Sudden Reckoning. How Big Tech Earnings Are Reshaping the AI Race. -- Barrons.com

31 oct 2025, 19:55 UTC

Charlas de Mercado

Crude Futures Fall for Third Straight Month -- Market Talk

31 oct 2025, 19:54 UTC

Adquisiciones, fusiones, absorciones

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

31 oct 2025, 19:54 UTC

Adquisiciones, fusiones, absorciones

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

31 oct 2025, 19:26 UTC

Charlas de Mercado

U.S. Natural Gas Rises on Winter Outlook, Strong LNG -- Market Talk

31 oct 2025, 18:30 UTC

Ganancias

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

31 oct 2025, 18:23 UTC

Charlas de Mercado

Gold Edges Lower for the Day, Closes October Positive -- Market Talk

31 oct 2025, 18:09 UTC

Ganancias

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31 oct 2025, 18:08 UTC

Ganancias

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31 oct 2025, 17:36 UTC

Charlas de Mercado

Grain Futures Shrug Off Stronger Dollar -- Market Talk

31 oct 2025, 17:31 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls, Natural Gas Rig Count Rises -- Market Talk

31 oct 2025, 17:16 UTC

Adquisiciones, fusiones, absorciones

Orange: Acquisition Likely Completed in First Half Next Year

31 oct 2025, 17:15 UTC

Adquisiciones, fusiones, absorciones

Orange: Agreement Set to Be Signed By Year-Out

31 oct 2025, 17:14 UTC

Adquisiciones, fusiones, absorciones

Orange: Acquisition Will Strengthen Position in Spain

31 oct 2025, 17:13 UTC

Adquisiciones, fusiones, absorciones

Orange Will Be Sole Owner of Spain's MasOrange Following Acquisition of Lorca's Stake

31 oct 2025, 17:12 UTC

Adquisiciones, fusiones, absorciones

Orange Reaches Deal to Buy Lorca's 50% Stake in MasOrange for EUR4.25B

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

26.47% repunte

Estimación a 12 meses

Media 257.63 USD 26.47%

Máximo 307 USD

Mínimo 220 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

16 ratings

Comprar

Mantener

Vender

De acuerdo con 16 analistas que ofrecen calificaciones bursátiles a para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

160 / 373 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.